MY166063A - Intravenous antiviral treatments - Google Patents

Intravenous antiviral treatments

Info

Publication number
MY166063A
MY166063A MYPI20083086A MYPI20083086A MY166063A MY 166063 A MY166063 A MY 166063A MY PI20083086 A MYPI20083086 A MY PI20083086A MY PI20083086 A MYPI20083086 A MY PI20083086A MY 166063 A MY166063 A MY 166063A
Authority
MY
Malaysia
Prior art keywords
antiviral treatments
intravenous
intravenous antiviral
treatments
kits
Prior art date
Application number
MYPI20083086A
Other languages
English (en)
Inventor
Yarlagadda Sudhakara Babu
Pooran Chand
Shanta Bantia
Shane Arnold
John Michael Kilpatrick
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY166063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MY166063A publication Critical patent/MY166063A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI20083086A 2006-02-13 2008-08-13 Intravenous antiviral treatments MY166063A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments
PCT/US2007/003755 WO2007095218A1 (en) 2006-02-13 2007-02-12 Intravenous antiviral treatments

Publications (1)

Publication Number Publication Date
MY166063A true MY166063A (en) 2018-05-23

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20083086A MY166063A (en) 2006-02-13 2008-08-13 Intravenous antiviral treatments

Country Status (11)

Country Link
EP (1) EP1986626A1 (enExample)
JP (3) JP2009538822A (enExample)
KR (9) KR102323339B1 (enExample)
AU (2) AU2007215156A1 (enExample)
BR (1) BRPI0707769A2 (enExample)
CA (1) CA2642260C (enExample)
EA (1) EA025483B1 (enExample)
HK (1) HK1212250A1 (enExample)
MX (2) MX393640B (enExample)
MY (1) MY166063A (enExample)
WO (1) WO2007095218A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102323339B1 (ko) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263179T3 (es) * 1996-06-14 2006-12-01 Biocryst Pharmaceuticals Inc. Compuestos de clopentano sustituido como inhibidores de la neuraminidasa.
BR9813480A (pt) * 1997-12-17 2000-10-10 Biocryst Pharm Inc Compostos inibidores de neuraminidase de ciclopentano substituìdo, composição e métodos de inibição da neuraminidase do vìrus da influenza- e de tratamento de infecção por vìrus da influenza-
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
KR102323339B1 (ko) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료

Also Published As

Publication number Publication date
BRPI0707769A2 (pt) 2011-05-10
CA2642260A1 (en) 2007-08-23
KR102267754B1 (ko) 2021-06-23
KR102323339B1 (ko) 2021-11-08
KR20200143519A (ko) 2020-12-23
KR20210135632A (ko) 2021-11-15
MX393640B (es) 2025-03-21
HK1212250A1 (en) 2016-06-10
EP1986626A1 (en) 2008-11-05
KR101992585B9 (ko) 2022-09-20
KR102475176B1 (ko) 2022-12-07
KR102194015B1 (ko) 2020-12-22
MX2008010394A (es) 2009-01-12
WO2007095218A1 (en) 2007-08-23
KR20160129105A (ko) 2016-11-08
KR20080096829A (ko) 2008-11-03
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
KR20140132778A (ko) 2014-11-18
CA2642260C (en) 2016-08-09
KR101992585B1 (ko) 2019-06-25
JP2015180695A (ja) 2015-10-15
KR20180024027A (ko) 2018-03-07
KR20210076189A (ko) 2021-06-23
JP6073202B2 (ja) 2017-02-01
EA200870263A1 (ru) 2009-06-30
EA025483B1 (ru) 2016-12-30
KR20230003248A (ko) 2023-01-05
KR20190072681A (ko) 2019-06-25
AU2007215156A1 (en) 2007-08-23
MX2020002008A (es) 2020-07-13
JP2013256527A (ja) 2013-12-26
JP2009538822A (ja) 2009-11-12

Similar Documents

Publication Publication Date Title
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
WO2009105513A8 (en) Novel compounds and methods for therapy
WO2008127364A3 (en) Antiviral compounds and use thereof
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
WO2009149179A3 (en) Enhanced antiviral therapy methods and devices
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
WO2008115281A3 (en) Compounds for treating viral infections
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
TW200738270A (en) Method of treating depression using a TNFα antibody
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MXPA04006572A (es) Terapia de combinacion antivirica.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
TNSN08496A1 (en) Aminothiazoles and their uses
MX2009009693A (es) Metodos para activar irs-1 y akt.
WO2007132355A3 (en) Compositions and methods for inhibiting viral adhesion
MY166063A (en) Intravenous antiviral treatments
TN2009000495A1 (en) Macrocycles and their uses